T. Yamazaki

发表

Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.

M. Sakaitani, Y. Isshiki, N. Shimma, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of novel fungal chitin synthase inhibitors.

Y. Isshiki, N. Shimma, M. Sudoh, 2000, Bioorganic & medicinal chemistry letters.

Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 1.

T. Watanabe, Y. Satoh, I. Horii, 2001, Bioorganic & medicinal chemistry letters.

Identification of a Novel Inhibitor Specific to the Fungal Chitin Synthase

M. Arisawa, N. Shimma, M. Sudoh, 2000, The Journal of Biological Chemistry.

Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.

Shigeo Sato, Sung-jin Kim, K. Kawasaki, 2014, Bioorganic & medicinal chemistry.

In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.

M. Page, M. Arisawa, Kazuko Kobayashi, 2010, International journal of antimicrobial agents.

Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.

N. Shimma, S. Ichihara, I. Umeda, 2002, Bioorganic & medicinal chemistry letters.

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Miyuki Yoshida, N. Ishii, Y. Aoki, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical The Selective Class I PI 3 K Inhibitor CH 5132799 Targets Human Cancers Harboring Oncogenic PIK 3 CA Mutations

Miyuki Yoshida, N. Ishii, Y. Aoki, 2011 .

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer

N. Ishii, Y. Aoki, O. Kondoh, 2013, Cancer science.

The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

M. Horinaka, T. Sakai, N. Katoh, 2014, PloS one.

Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.

Atsushi Suda, Hiroshi Koyano, Naomi Ono, 2012, Bioorganic & medicinal chemistry letters.

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers

Shigeo Sato, N. Ishii, Y. Aoki, 2012, Cancer science.

In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.

M. Page, M. Arisawa, Kazuko Kobayashi, 2010, International journal of antimicrobial agents.

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer

Y. Aoki, O. Kondoh, A. Suda, 2013, Cancer science.

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Miyuki Yoshida, Y. Aoki, O. Kondoh, 2011, Clinical Cancer Research.